Prophylactic HIV drugs Market
Market Insights on Prophylactic HIV drugs covering sales outlook, demand forecast & up-to-date key trends
Prophylactic HIV Drugs Market by Drug Class, Distributional Channel & Region - Forecast 2022 – 2032
Prophylactic HIV Drugs Market Snapshot (2022-2032)
[250 Pages Report] The global prophylactic HIV drugs market size reached a valuation of around US$ 30 Bn in 2021. Further, with rising prevalence of HIV infection worldwide and growing awareness about HIV AIDS prevention, the demand for prophylactic HIV drugs is projected to register 4%CAGR between 2022 and 2032, totaling over US$ 40 Bn in 2028
Report Attribute |
Details |
Prophylactic HIV Drugs Market Size (2021) |
US$ 30 Bn |
Prophylactic HIV Drugs Market Estimated Growth Rate (2022-2032) |
4% |
Prophylactic HIV Drugs Market Projected Size (2028) |
US$ 40 Bn |
Over the years, human immunodeficiency virus (HIV) has become one of the leading causes of death worldwide affecting millions of people. The virus targets the immune system of infected patients and makes them vulnerable to many infections and cancers.
Although there is no permanent cure available for HIV infection, the condition can be managed through increasing access to effective prevention, diagnosis, treatment, and care. Rising focus towards preventing acquisition of HIV is one of the major factors pushing the demand for prophylactic HIV drugs.
Prophylactic HIV drugs are advanced therapeutics used to prevent getting HIV infection in certain circumstances. They have especially effective in preventing acquisition of HIV from sex and injection drug use.
Amid rising prevalence of HIV, people across the world are showing a keen inclination towards consuming pre-exposure prophylaxis (PrEP) due to its better effectiveness. According to the Centers for Disease Control and Prevention (CDC), PrEP reduces the risk of getting HIV from sex and injection drug use by around 99% and 74% respectively.
Similarly, prophylactic HIV drugs such as antiretroviral (ARV) are gaining wider popularity due to their ability to prevent and control HIV infection.
Growing awareness among people regarding HIV and the benefits of prophylactic HIV drugs will continue to boost the sales of prophylactic HIV drugs during the forecast period.
Let us know your requirement to get
100% FREE customization
Which are the Factors Stimulating Growth in Prophylactic HIV Drugs Market?
Rapid surge in HIV cases worldwide, continuous novel drug launches and approvals, and increasing need for preventing and controlling HIV are some of the major factors stimulating the growth of prophylactic HIV drugs market.
Prophylactic HIV drugs have become highly sought-after therapeutics for preventing the acquisition of HIV infection among people who are at a high risk. Consumption of these drugs significantly reduces the chances of HIV infection. They are mostly recommended during sex and injection drug use where there is a high chance of HIV transmission.
Growing popularity of prophylactic HIV drugs on account of their better effectiveness and cost-effective nature is providing a strong thrust to the growth of prophylactic HIV drugs market and the trend is likely to continue during the forecast period.
Similarly, increasing prevalence of HIV and its high mortality rate are pushing the demand for therapeutics like prophylactic HIV drugs. According to the World Health Organization (WHO), there were around 1.5 million newly infected cases of HIV and over 680000 deaths in 2020. This is prompting people to use prophylactic HIV drugs.
In addition to this, increasing government initiatives and investments in spreading awareness among people about HIV, its symptoms, precautions and treatment is expected to further expand the prophylactic HIV drugs market size during the forecast period.
What are the Challenges Faced by Prophylactic HIV Drugs Market?
Despite its optimistic stance, there are certain obstacles that are challenging the growth of prophylactic HIV drugs market. Some of these obstacles include side effects associated with prophylactic HIV drugs, strict government approval for these drugs, and low awareness levels about these therapeutics across low emerging economies.
It has been observed that prophylactic HIV drugs often lead to side effects such as headache, depression, nausea, vomiting, and abdominal pain, etc. As a result, many people refrain from consuming these therapeutics. This in turn is limiting the growth of prophylactic HIV drugs market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWill North America Retain its Monopoly in the Global Prophylactic HIV Drugs Market?
According to Future Market Insights, North America is likely to retain its dominant position in the global prophylactic HIV drugs market, accounting for the largest market share through 2032. Growth in North America Prophylactic HIV drugs market is underpinned by presence of high level of awareness among people, surge in HIV infection cases, availability of advanced healthcare facilities, and growing adoption of new therapeutics.
Demand for prophylactic HIV drugs is especially rising across countries like the U.S. and Mexico due to surge in HIV cases. In recent years, there has been a rapid surge in cases of HIV infection in the U.S. due to rising incidence of unprotected sex and use of unsterile injections. According to the Centers for Disease Control and Prevention (CDC), there were around 34800 new HIV infection cases reported in the U.S. during 2019. This rise in HIV infection cases is playing a key role in pushing the growth of prophylactic HIV drugs market.
How Will Prophylactic HIV Drugs Market Fare in Europe?
Amid rising prevalence of HIV infection and increasing adoption of novel therapeutics, Europe prophylactic HIV drugs market is likely to grow at a considerable pace during the forecast period.
Over the last few decades, there has been a sharp rise in cases of HIV European countries like the U.K., Germany, and France due to various reasons. As per the European Centre for Disease Prevention and Control, over 2.2 million people have been diagnosed and reported with HIV in the WHO European Region during the last three decades. This in turn is fostering the growth of prophylactic HIV drugs market in the region.
Furthermore, presence of leading manufacturers such as ViiV Health is positively impacting the growth of prophylactic HIV drugs market across Europe.

A unified Market Research Subscription Platform, built for today's disparate research needs.
Market Competition
Some of the leading manufacturers of prophylactic HIV drugs include Gilead Sciences, Inc, Merck Sharp & Dohme Corp., Merck & Co. Inc., Mylan NV, Cipla Inc., Genentech Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Health Care Systems Inc.
These key players are rigorously investing in research and development to advance in HIV therapeutics. They have adopted strategies such as new product launches and approvals, mergers, partnerships, acquisitions, launching awareness campaigns, etc. to expand their customer bases as well as to gain an upper hand in the global prophylactic HIV drugs market. For instance, in December 2021, the U.S. Food and Drug Administration approved first injectable treatment “Apretude” for HIV pre-exposure prevention.
Report Scope
Report Attribute |
Details |
Growth Rate |
CAGR of 4% from 2022 to 2032 |
Projected Market Valuation (2032) |
US$ 40 Bn |
Base Year for Estimation |
2021 |
Historical Data |
2015-2020 |
Forecast Period |
2022-2032 |
Quantitative Units |
Revenue in US$ Billion and CAGR from 2022-2032 |
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization |
Available Upon Request |
Key Segments Profiled in the Prophylactic HIV Drugs Industry Survey
By Drug Class:
- Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)
- Integrase Inhibitor
By Distributional Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Mail Order Pharmacies
- Drug Stores
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- Middle East and Africa
Frequently Asked Questions
FMI predicts the global prophylactic HIV drugs market to grow at a steady CAGR of around 4% throughout the forecast period.
North America is likely to account for the largest share of the global prophylactic HIV drugs market through 2032.
Gilead Sciences, Inc, Merck Sharp & Dohme Corp., Merck & Co. Inc., Mylan NV, Cipla Inc., Genentech Inc., and Bristol-Myers Squibb Company are some prominent prophylactic HIV drug manufacturers
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Drug Class, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Drug Class, 2022-2032
5.3.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)
5.3.2. Integrase Inhibitor
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032
6. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Distributional Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Distributional Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2022-2032
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Mail Order Pharmacies
6.3.4. Drug Stores
6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2022-2032
7. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distributional Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distributional Channel
8.4. Key Takeaways
9. Latin America Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distributional Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distributional Channel
9.4. Key Takeaways
10. Europe Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distributional Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distributional Channel
10.4. Key Takeaways
11. Asia Pacific Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Malaysia
11.2.1.5. Singapore
11.2.1.6. Australia
11.2.1.7. New Zealand
11.2.1.8. Rest of APAC
11.2.2. By Drug Class
11.2.3. By Distributional Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distributional Channel
11.4. Key Takeaways
12. MEA Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Drug Class
12.2.3. By Distributional Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distributional Channel
12.4. Key Takeaways
13. Key Countries Prophylactic HIV drugs Market Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Drug Class
13.1.2.2. By Distributional Channel
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Drug Class
13.2.2.2. By Distributional Channel
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Drug Class
13.3.2.2. By Distributional Channel
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Drug Class
13.4.2.2. By Distributional Channel
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Drug Class
13.5.2.2. By Distributional Channel
13.6. U.K.
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Drug Class
13.6.2.2. By Distributional Channel
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Drug Class
13.7.2.2. By Distributional Channel
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Drug Class
13.8.2.2. By Distributional Channel
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Drug Class
13.9.2.2. By Distributional Channel
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Drug Class
13.10.2.2. By Distributional Channel
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Drug Class
13.11.2.2. By Distributional Channel
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Drug Class
13.12.2.2. By Distributional Channel
13.13. Malaysia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Drug Class
13.13.2.2. By Distributional Channel
13.14. Singapore
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Drug Class
13.14.2.2. By Distributional Channel
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Drug Class
13.15.2.2. By Distributional Channel
13.16. New Zealand
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Drug Class
13.16.2.2. By Distributional Channel
13.17. GCC Countries
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Drug Class
13.17.2.2. By Distributional Channel
13.18. South Africa
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Drug Class
13.18.2.2. By Distributional Channel
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Drug Class
13.19.2.2. By Distributional Channel
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Drug Class
14.3.3. By Distributional Channel
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Gilead Sciences
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.1.5.2. Product Strategy
15.1.1.5.3. Channel Strategy
15.1.2. Merck Sharp & Dohme Corp.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.2.5.2. Product Strategy
15.1.2.5.3. Channel Strategy
15.1.3. AbbVie
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.3.5.2. Product Strategy
15.1.3.5.3. Channel Strategy
15.1.4. APOTEX INC.
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.4.5.2. Product Strategy
15.1.4.5.3. Channel Strategy
15.1.5. Auro Pharma Inc.
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.5.5.2. Product Strategy
15.1.5.5.3. Channel Strategy
15.1.6. Boehringer Ingelheim International GmbH
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.6.5.2. Product Strategy
15.1.6.5.3. Channel Strategy
15.1.7. Bristol-Myers Squibb Company
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.7.5.2. Product Strategy
15.1.7.5.3. Channel Strategy
15.1.8. Cipla Inc.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.8.5.2. Product Strategy
15.1.8.5.3. Channel Strategy
15.1.9. GalaxoSmithKline PLC
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.9.5.2. Product Strategy
15.1.9.5.3. Channel Strategy
15.1.10. Genentech Inc.
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.10.5.2. Product Strategy
15.1.10.5.3. Channel Strategy
15.1.11. Mylan NV
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
15.1.11.5.2. Product Strategy
15.1.11.5.3. Channel Strategy
15.1.12. Pfizer Inc.
15.1.12.1. Overview
15.1.12.2. Product Portfolio
15.1.12.3. Profitability by Market Segments
15.1.12.4. Sales Footprint
15.1.12.5. Strategy Overview
15.1.12.5.1. Marketing Strategy
15.1.12.5.2. Product Strategy
15.1.12.5.3. Channel Strategy
15.1.13. Teva Pharmaceutical Industries Ltd
15.1.13.1. Overview
15.1.13.2. Product Portfolio
15.1.13.3. Profitability by Market Segments
15.1.13.4. Sales Footprint
15.1.13.5. Strategy Overview
15.1.13.5.1. Marketing Strategy
15.1.13.5.2. Product Strategy
15.1.13.5.3. Channel Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Prophylactic HIV drugs Market Volume (Tons) Forecast by Region, 2017-2032
Table 3: Global Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 4: Global Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032
Table 5: Global Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 6: Global Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 7: North America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: North America Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 9: North America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 10: North America Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032
Table 11: North America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 12: North America Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 13: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Latin America Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 15: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 16: Latin America Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032
Table 17: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 18: Latin America Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 19: Europe Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 20: Europe Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 21: Europe Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 22: Europe Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032
Table 23: Europe Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 24: Europe Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 25: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 26: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 27: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 28: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032
Table 29: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 30: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 31: MEA Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 32: MEA Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 33: MEA Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 34: MEA Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032
Table 35: MEA Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 36: MEA Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 2: Global Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 3: Global Prophylactic HIV drugs Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 5: Global Prophylactic HIV drugs Market Volume (Tons) Analysis by Region, 2017-2032
Figure 6: Global Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 9: Global Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032
Figure 10: Global Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 11: Global Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 12: Global Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 13: Global Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 14: Global Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 15: Global Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 16: Global Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032
Figure 17: Global Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 18: Global Prophylactic HIV drugs Market Attractiveness by Region, 2022-2032
Figure 19: North America Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 20: North America Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 21: North America Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 22: North America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 23: North America Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 24: North America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 25: North America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 26: North America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 27: North America Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032
Figure 28: North America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 29: North America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 30: North America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 31: North America Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 32: North America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 33: North America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 34: North America Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032
Figure 35: North America Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 36: North America Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032
Figure 37: Latin America Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 38: Latin America Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 39: Latin America Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 40: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 41: Latin America Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 42: Latin America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 43: Latin America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 44: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 45: Latin America Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032
Figure 46: Latin America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 47: Latin America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 48: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 49: Latin America Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 50: Latin America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 51: Latin America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 52: Latin America Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032
Figure 53: Latin America Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 54: Latin America Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032
Figure 55: Europe Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 56: Europe Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 57: Europe Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 58: Europe Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 59: Europe Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 60: Europe Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 61: Europe Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 62: Europe Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 63: Europe Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032
Figure 64: Europe Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 65: Europe Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 66: Europe Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 67: Europe Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 68: Europe Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 69: Europe Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 70: Europe Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032
Figure 71: Europe Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 72: Europe Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032
Figure 73: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 74: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 75: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 76: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 77: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 78: Asia Pacific Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 79: Asia Pacific Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 80: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 81: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032
Figure 82: Asia Pacific Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 83: Asia Pacific Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 84: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 85: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 86: Asia Pacific Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 87: Asia Pacific Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 88: Asia Pacific Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032
Figure 89: Asia Pacific Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 90: Asia Pacific Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032
Figure 91: MEA Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 92: MEA Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 93: MEA Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 94: MEA Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 95: MEA Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 96: MEA Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 97: MEA Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 98: MEA Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 99: MEA Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032
Figure 100: MEA Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 101: MEA Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 102: MEA Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 103: MEA Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 104: MEA Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 105: MEA Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 106: MEA Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032
Figure 107: MEA Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 108: MEA Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports